Covered recipient · General Payments record
CATHERINE DIEFENBACH
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$92,117.94
- Reported across 147 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $10,192.50 | 4 |
| Travel and Lodging | $1,117.79 | 3 |
| Food and Beverage | $629.44 | 8 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $6,322.84 | 6 |
| Acerta Pharma LLC | $2,740.00 | 1 |
| Kite Pharma, Inc. | $2,390.00 | 1 |
| Genentech USA, Inc. | $162.40 | 2 |
| PFIZER INC. | $160.05 | 2 |
| E.R. Squibb & Sons, L.L.C. | $86.44 | 2 |
| BeiGene USA, Inc. | $78.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $142.55 | 06/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103640716 | CMS |
| ABBVIE INC. | $374.51 | 06/02/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104183276 | CMS |
| ABBVIE INC. | $536.20 | 06/03/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104183278 | CMS |
| ABBVIE INC. | $4,387.50 | 07/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103133671 | CMS |
| ABBVIE INC. | $207.08 | 07/01/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104183280 | CMS |
| ABBVIE INC. | $675.00 | 08/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103133673 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,740.00 | 01/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105394599 | CMS |
| BeiGene USA, Inc. | $78.00 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120851282 | CMS |
| E.R. Squibb & Sons, L.L.C. | $59.43 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101439620 | CMS |
| E.R. Squibb & Sons, L.L.C. | $27.01 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101439622 | CMS |
| Genentech USA, Inc. | $71.63 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132985199 | CMS |
| Genentech USA, Inc. | $90.77 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132985203 | CMS |
| Kite Pharma, Inc. | $2,390.00 | 06/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1128609575 | CMS |
| PFIZER INC. | $85.48 | 10/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131363031 | CMS |
| PFIZER INC. | $74.57 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131393900 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.